Synthesis of NSAIDs–Se derivatives as potent anticancer agents
In the present study, a series of NSAIDs–Se derivatives include selenocyanates and diselenides were synthesized and characterized, their anticancer activities against the human cancer cell lines SW480, HeLa, A549, and HepG2 were determined. Interestingly, most of the new compounds showed active in reducing the viability of different cancer lines. Compounds 1a and 1m exhibited higher promising activities than other derivatives. As the most active compound 1a showed IC50 values lower than 20 μM against the four cancer cell lines, particularly against SW480 with IC50 values below 10 μm, it shows the potential to be a promising molecular chemotherapeutic agent for colorectal cancer.
KeywordsSelenocyanates Diselenides NSAIDs Anticaner
This investigation was made possible through the financial support of National Natural Science Foundation of China (Grant No: 21302065).
Compliance with ethical standards
Conflict of interest
We declare that we have no financial and personal relationships with other people or organizations that caninappropriately influence our work, there is no professional or other personal interest of any nature or kind inany product, service and/or company that could be construed as influencing the position presented in, or thereview of, the manuscript entitled “Synthesis of NSAIDs–Se derivatives as potent anticancer agents”.
- Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC (2006) Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66:1070–1075CrossRefPubMedGoogle Scholar
- Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K (2007) Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 120:1410–1417CrossRefPubMedGoogle Scholar
- Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612CrossRefPubMedGoogle Scholar